Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schultz Exits: Pressures From Inside And Out Catch Up With CDRH Director

This article was originally published in The Gray Sheet

Executive Summary

At least a handful of disgruntled employees, members of Congress champing at the bit and a new reformist FDA administration were apparently the undoing of Dan Schultz's leadership of CDRH
Advertisement

Related Content

Director Of 510(k) Pre-Market Notification Staff Makes Her Exit
Q&A: Former CDRH Director Dan Schultz On Communication Issues, 510(k)s
Tillman Departs: Device Evaluation Director To Leave FDA March 26
People In Brief
Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk
CDRH Acting Director Jeffrey Shuren Vies For Permanent Spot
FDA Asks Institute Of Medicine To Evaluate 510(k) Review Process
FDA Device Center Loses Another Top Staffer
Sports Medicine: Game-Changing Technologies
“Ordered, Intimidated And Coerced”? CDRH Targeted In Misconduct Probe

Topics

Advertisement
UsernamePublicRestriction

Register

MT027800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel